|
Age (> 60 vs. ≤ 60)
|
1.80 (0.98–3.81)
|
0.065
|
1.04 (0.52–2.30)
|
0.205
|
|
Gender (male vs. female)
|
1.45 (1.07–1.92)
|
0.052
|
0.29 (0.13–0.86)
|
0.905
|
|
B symptoms (yes vs. no)
|
0.68 (0.24–1.63)
|
0.024
|
0.35 (0.12–1.98)
|
0.032
|
|
Lugano stage (I–II2 vs. III–IV)
|
2.28 (1.28–4.14)
|
0.001
|
1.52 (0.65–3.58)
|
0.018
|
|
LDH (elevated vs. normal)
|
1.31 (1.04–1.67)
|
0.015
|
0.67 (0.33–1.42)
|
0.327
|
|
Local tumor invasiveness (yes vs. no)
|
0.46 (0.22–0.96)
|
0.024
|
0.32 (0.15–0.66)
|
0.037
|
|
Treatment (chemotherapy or radiotherapy vs. both)
|
0.67 (0.33–1.42)
|
0.004
|
0.35 (0.12–2.30)
|
0.041
|
|
Absolute lymphocyte count (≤ 1.5 × 109/L vs. > 1.5 × 109/L)
|
1.56 (0.72–3.40)
|
0.002
|
1.24 (0.62–2.08)
|
0.006
|
|
Absolute monocyte count (≤ 0.5 × 109/L vs. > 0.5 × 109/L)
|
0.53 (0.21–1.37)
|
0.102
|
0.45 (0.13–2.49)
|
0.361
|
|
LMR (≤ 2.7 vs. > 2.7)
|
4.21 (1.53–11.56)
|
0.000
|
2.78 (1.15–6.76)
|
0.034
|
